Download PDF
Planta Med 2010; 76(14): 1544-1549
DOI: 10.1055/s-0030-1249805
Pharmacology
Original Papers
© Georg Thieme Verlag KG Stuttgart · New York

Kansuinine A and Kansuinine B from Euphorbia kansui L. Inhibit IL-6-induced Stat3 Activation

Jong Sun Chang1 [*] , Seung Woong Lee1 [*] , Mi Hye Park1 , Myo Sun Kim1 , Barry I. Hudson2 , Su-Jin Park1 , Woo Song Lee1 , Mun-Chual Rho1
  • 1Korea Research Institute of Bioscience and Biotechnology, Jeongeup-si, Korea
  • 2Division of Surgical Science, Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, NY, USA
Further Information

Publication History

received October 19, 2009 revised February 11, 2010

accepted March 10, 2010

Publication Date:
08 April 2010 (online)

    Permissions and Reprints

Abstract

The current study was performed to examine the mechanisms underlying the potential effects of E. kansui on IL-6-induced cellular signaling in human hepatoma cells. We found that two diterpenoids, kansuinine A and B, from E. kansui have an inhibitory effect on IL-6-induced Stat3 activation by activating ERK1/2. Inhibition of MEK significantly blocked the effects of kansuinine A and B on IL-6-induced Stat3 activation and tyrosine phosphorylation. These results suggest that blocking of IL-6-induced signal transduction is partially due to the sustained activation of ERK1/2 by kansuinine A and B, which in turn results in an increase of Stat3 serine phosphorylation and SOCS-3 expression. Treatment with kansuinine A and B represents a novel method to block these IL-6-induced effects.

Key words

Euphorbia kansui Liou - Euphorbiaceae - kansuinine A - kansuinine B - IL‐6 - Stat3 - ERK1/2

References

  • 1 Strassmann G, Masui Y, Chizzonite R, Fong M. Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon 26 tumor.  J Immunol. 1993;  150 2341-2345
    PubMedGoogle Scholar
  • 2 Luger T A, Schwarz T, Krutmann J, Kirnbauer R, Neuner P, Kock A, Urbanski A, Borth W, Schauer E. Interleukin-6 is produced by epidermal cells and plays an important role in the activation of human T-lymphocytes and natural killer cells.  Ann NY Acad Sci. 2008;  557 405-414
    CrossrefPubMedGoogle Scholar
  • 3 Neveu W A, Allard J B, Dienz O, Wargo M J, Ciliberto G, Whittaker L A, Rincon M. IL-6 is required for airway mucus production induced by inhaled fungal allergens.  J Immunol. 2009;  183 1732-1738
    CrossrefPubMedGoogle Scholar
  • 4 Barton B E. IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation.  Immunol Res. 2001;  23 41-58
    CrossrefPubMedGoogle Scholar
  • 5 Morishima A, Marui A, Shimamoto T, Saji Y, Nishina T, Komeda M. A case of interleukin-6-producing cardiac myxoma resembling multicentric Castleman's disease.  J Thorac Cardiovasc Surg. 2009;  138 499-501
    CrossrefPubMedGoogle Scholar
  • 6 Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis: evidence of safety and efficacy in a 5-year extension study.  Ann Rheum Dis. 2009;  68 1580-1584
    CrossrefPubMedGoogle Scholar
  • 7 Mori A, Toyoshima N, Saito M, Oka T, Irie T, Morioka M. Hypercalcemia and multiple osteolytic lesions associated with proinflammatory cytokines in a patient with acute lymphoblastic leukemia.  Rinsho Ketsueki. 2007;  48 559-564
    PubMedGoogle Scholar
  • 8 Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, Patel N, Smith E S, Wang W, Prabhala R, Tai Y T, Tassone P, Anderson K C, Munshi N C. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.  Clin Cancer Res. 2009;  15 7144-7152
    CrossrefPubMedGoogle Scholar
  • 9 Hayashi M, Rho M C, Enomoto A, Fukami A, Kim Y P, Kikuchi Y, Sunazuka T, Hirose T, Komiyama K, Omura S. Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130.  Proc Natl Acad Sci USA. 2002;  99 14728-14733
    CrossrefPubMedGoogle Scholar
  • 10 Lütticken C, Wegenka U M, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur A G, Wilks A F, Yasukawa K, Taga T et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130.  Science. 1994;  263 89-92
    CrossrefPubMedGoogle Scholar
  • 11 Ihle J N. STATs: signal transducers and activators of transcription.  Cell. 1996;  84 331-334
    CrossrefPubMedGoogle Scholar
  • 12 Sebt S M, Der C J. Opinion: searching for the elusive targets of farnesyltransferase inhibitors.  Nat Rev Cancer. 2003;  3 945-951
    CrossrefPubMedGoogle Scholar
  • 13 Darnell Jr J E. STATs and gene regulation.  Science. 1997;  277 1630-1635
    CrossrefPubMedGoogle Scholar
  • 14 Aaronson D S, Horvath C M. A road map for those who don't know JAK-STAT.  Science. 2003;  296 1653-1655
    PubMedGoogle Scholar
  • 15 Sengupta T K, Talbot E S, Scherle P A, Ivashkiv L B. Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogenactivated protein kinases.  Proc Natl Acad Sci USA. 1998;  95 1110-1112
    PubMedGoogle Scholar
  • 16 Boulton T G, Nye S H, Robbins D J, Ip N Y, Radziejewska E, Morgenbesser S D, DePinho R A, Panayotatos N, Cobb M H, Yancopoulos G D. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF.  Cell. 1991;  65 663-675
    CrossrefPubMedGoogle Scholar
  • 17 Woodgett J R, Kyriakis J M, Avruch J, Zon L I, Zanke D J. Reconstitution of novel signalling cascades responding to cellular stresses.  Philos Trans R Soc Lond B Biol Sci. 1996;  351 135-141
    PubMedGoogle Scholar
  • 18 Marshall C J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.  Cell. 1995;  80 179-185
    CrossrefPubMedGoogle Scholar
  • 19 David M, Petricoin 3rd E, Benjamin C, Pine R, Weber M J, Larner A C. Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins.  Science. 1995;  22 1721-1723
    PubMedGoogle Scholar
  • 20 Ihara S, Nakajima K, Fukada T, Hibi M, Nagata S, Hirano T, Fukui Y. Dual control of neurite outgrowth by STAT3 and MAP kinase in PC12 cells stimulated with interleukin-6.  EMBO J. 1997;  16 5345-5352
    CrossrefPubMedGoogle Scholar
  • 21 Boccaccio C, Andò M, Tamagnone L, Bardelli A, Michieli P, Battistini C, Comoglio P M. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway.  Nature. 1998;  391 285-288
    CrossrefPubMedGoogle Scholar
  • 22 Alessi D R, Cuenda A, Cohen P, Dudley D T, Saltiel A R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo.  J Biol Chem. 1995;  270 27489-27494
    CrossrefPubMedGoogle Scholar
  • 23 Dudley D T, Pang L, Decker S J, Bridges A J, Saltiel A R. A synthetic inhibitor of the mitogen activated protein kinase cascade.  Proc Natl Acad Sci USA. 1995;  92 7686-7689
    CrossrefPubMedGoogle Scholar
  • 24 Wu T S, Lin Y M, Haruna M, Pan D J, Shingu T, Chen Y P, Hsu H Y. Antitumor agents, 119. Kansuiphorins A and B, two novel antileukemic diterpene esters from Euphorbia kansui.  J Nat Prod. 1991;  54 823-829
    CrossrefPubMedGoogle Scholar
  • 25 Yu F R, Lian X Z, Guo H Y, McGuire P M, Li R D, Wang R, Yu F H. Isolation and characterization of methyl esters and derivatives from Euphorbia kansui (Euphorbiaceae) and their inhibitory effects on the human SGC-7901 cells.  J Pharm Pharm Sci. 2005;  8 528-535
    PubMedGoogle Scholar
  • 26 Yasukawa K, Akihisa T, Yoshida Z Y, Takido M. Inhibitory effect of euphol, a triterpene alcohol from the roots of Euphorbia kansui, on tumour promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin.  J Pharm Pharmacol. 2000;  52 119-124
    CrossrefPubMedGoogle Scholar
  • 27 Zheng W F, Cui Z, Zhu Q. Cytotoxicity and antiviral activity of the compounds from Euphorbia kansui.  Planta Med. 1998;  64 754-756
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Okouchi T, Abe T, Araki S, Arai S, Iida T, Wang L Y, Kitanaka S, Miyata S. Mechanism of proliferation arrest of embryonic cells of Xenopus by diterpene compounds.  Bioorg Med Chem. 2005;  13 3847-3851
    CrossrefPubMedGoogle Scholar
  • 29 Miyata S, Wang L Y, Wang N L, Yao X S, Kitanaka S. Selective inhibition of the growth of cancer cells by diterpenes selected with embryonic cells of Xenopus.  Cell Biol Int. 2004;  28 179-184
    CrossrefPubMedGoogle Scholar
  • 30 Miyata S, Wang L Y, Yoshida C, Kitanaka S. Inhibition of cellular proliferation by diterpenes, topoisomerase II inhibitor.  Bioorg Med Chem. 2006;  14 2048-2051
    CrossrefPubMedGoogle Scholar
  • 31 Pan Q, Min Z D. Studies on the structure of kansuinine A from Euphorbia kansui.  Chin Chem Lett. 2002;  13 1178-1180
    PubMedGoogle Scholar
  • 32 Qin B, Perry L G, Broeckling C D, Du J, Stermitz F R, Paschke M W, Vivanco J M. Phytotoxic allelochemicals from roots and root exudates of leafy spurge (Euphorbia esula L.).  Plant Signal Behav. 2006;  1 323-327
    PubMedGoogle Scholar
  • 33 Yan S F, Zou Y S, Gao Y, Zhai C, Mackman N, Lee S L, Milbrandt J, Pinsky D, Kisiel W, Stern D. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia.  Proc Natl Acad Sci USA. 1998;  95 8298-8303
    CrossrefPubMedGoogle Scholar
  • 34 Tenhumberg S, Schuster B, Zhu L, Kovaleva M, Scheller J, Kallen K J, Rose-John S. gp130 Dimerization in the absence of ligand: preformed cytokine receptor complexes.  Biochem Biophys Res Commun. 2006;  346 649-657
    CrossrefPubMedGoogle Scholar
  • 35 Nicholas A C, David S, James A J. Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p 120 RasGAP and activates Ras.  Nat Cell Biol. 2001;  3 460-465
    CrossrefPubMedGoogle Scholar
  • 36 Joanna B, Kshipra S, Dhammika N, Stephen O D, Agnes M R, Antonio E, Babu L K. A Survey of synthetic and natural phytotoxic compounds and phytoalexins as potential antimalarial compounds.  Biol Pharm Bull. 2007;  30 1740-1744
    CrossrefPubMedGoogle Scholar
  • 37 Wätjen W, Debbab A, Hohlfeld A, Chovolou Y, Kampkötter A, Edrada R A, Ebel R, Hakiki A, Mosaddak M, Totzke F, Kubbutat M H, Proksch P. Enniatins A1, B and B1 from an endophytic strain of Fusarium tricinctum induce apoptotic cell death in H4IIE hepatoma cells accompanied by inhibition of ERK phosphorylation.  Mol Nutr Food Res. 2009;  53 431-440
    CrossrefPubMedGoogle Scholar
  • 38 Aithal B K, Kumar M R, Rao B N, Udupa N, Rao B S. Juglone, a naphthoquinone from walnut, exerts cytotoxic and genotoxic effects against cultured melanoma tumor cells.  Cell Biol Int. 2009;  33 1039-1049
    CrossrefPubMedGoogle Scholar
  • 39 Lara T, Petros G, Johannes G B, Fred S, Peter C H, Lutz G. The inhibition of interleukin-6 dependent STAT activation by mitogen-activated protein kinases depends on tyrosine 759 in the cytoplasmic tail of glycoprotein 130.  J Biol Chem. 2000;  275 18810-18817
    CrossrefPubMedGoogle Scholar
  • 40 Kolaparthi V, Ahsan C, James W F. Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3 (Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases.  Cancer Res. 2005;  65 2861-2871
    CrossrefPubMedGoogle Scholar
  • 41 Lee H K, Jung J, Lee S H, Seo S Y, Suh D J, Park H T. Extracellular signal-regulated kinase activation is required for serine 727 phosphorylation of STAT3 in Schwann cells in vitro and in vivo.  Kor J Physiol Pharmacol. 2009;  13 161-168
    PubMedGoogle Scholar
  • 42 Chung J, Uchida E, Grammer T C, Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation.  Mol Cell Biol. 1997;  17 6508-6516
    PubMedGoogle Scholar
  • 43 Beadling C, Ng J, Babbage J W, Cantrell D A. Interleukin-2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway.  EMBO J. 1996;  15 1902-1913
    PubMedGoogle Scholar
  • 44 Narayana Y, Bansal K, Sinha A Y, Kapoor N, Puzo G, Gilleron M, Balaji K N. SOCS3 expression induced by PIM2 requires PKC and PI3K signaling.  Mol Immunol. 2009;  46 2947-2954
    CrossrefPubMedGoogle Scholar
  • 45 Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation.  Nat Rev Immunol. 2007;  7 454-465
    CrossrefPubMedGoogle Scholar
  • 46 Huang K C, Chen C W, Chen J C, Lin W W. Statins induce suppressor of cytokine signaling-3 in macrophages.  FEBS Lett. 2003;  555 385-389
    CrossrefPubMedGoogle Scholar

1 These authors equally contributed to this work.

Mun-Chual Rho, Ph.D.

Bioindustry Research Center
Korea Research Institute of Bioscience and Biotechnology

1404 Sinjeong-dong

Jeongeup-si, Jeonbuk, 580-185

Korea

Phone: + 82 6 35 70 52 30

Fax: + 82 6 35 70 52 39

Email: rho-m@kribb.re.kr

Woo Song Lee, Ph.D.

Bioindustry Research Center
Korea Research Institute of Bioscience and Biotechnology

1404 Sinjeong-dong

Jeongeup-si, Jeonbuk, 580-185

Korea

Phone: + 82 6 35 70 51 70

Fax: + 82 6 35 70 52 39

Email: wslee@kribb.re.kr

      >